KR101626108B1 - Composition containing lobate campion extract - Google Patents
Composition containing lobate campion extract Download PDFInfo
- Publication number
- KR101626108B1 KR101626108B1 KR1020140009097A KR20140009097A KR101626108B1 KR 101626108 B1 KR101626108 B1 KR 101626108B1 KR 1020140009097 A KR1020140009097 A KR 1020140009097A KR 20140009097 A KR20140009097 A KR 20140009097A KR 101626108 B1 KR101626108 B1 KR 101626108B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- present
- flower
- activity
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 78
- 239000000284 extract Substances 0.000 title claims description 64
- 241000083473 Lychnis Species 0.000 title description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 18
- 239000000419 plant extract Substances 0.000 claims description 16
- 239000004480 active ingredient Substances 0.000 claims description 15
- 239000003963 antioxidant agent Substances 0.000 claims description 14
- 239000002537 cosmetic Substances 0.000 claims description 7
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 claims description 7
- 230000002292 Radical scavenging effect Effects 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 235000013402 health food Nutrition 0.000 claims description 2
- 241000225018 Silene cognata Species 0.000 claims 2
- 230000003064 anti-oxidating effect Effects 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 41
- 230000000694 effects Effects 0.000 description 35
- 102100020720 Calcium channel flower homolog Human genes 0.000 description 34
- 101000932468 Homo sapiens Calcium channel flower homolog Proteins 0.000 description 34
- 238000002835 absorbance Methods 0.000 description 24
- 102000003425 Tyrosinase Human genes 0.000 description 20
- 108060008724 Tyrosinase Proteins 0.000 description 20
- 102000016387 Pancreatic elastase Human genes 0.000 description 18
- 108010067372 Pancreatic elastase Proteins 0.000 description 18
- 230000002087 whitening effect Effects 0.000 description 18
- 235000019441 ethanol Nutrition 0.000 description 17
- 241000196324 Embryophyta Species 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 238000009472 formulation Methods 0.000 description 14
- 235000006708 antioxidants Nutrition 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 230000003712 anti-aging effect Effects 0.000 description 12
- 238000000605 extraction Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- -1 DPPH radicals Chemical class 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 230000037303 wrinkles Effects 0.000 description 8
- 230000002335 preservative effect Effects 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000013329 compounding Methods 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 229930003427 Vitamin E Natural products 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 210000003477 cochlea Anatomy 0.000 description 5
- 238000004040 coloring Methods 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 5
- 229960004705 kojic acid Drugs 0.000 description 5
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000007901 soft capsule Substances 0.000 description 5
- 235000019165 vitamin E Nutrition 0.000 description 5
- 229940046009 vitamin E Drugs 0.000 description 5
- 239000011709 vitamin E Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 3
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 3
- 229920002498 Beta-glucan Polymers 0.000 description 3
- 241000218631 Coniferophyta Species 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000001263 FEMA 3042 Substances 0.000 description 3
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 235000006886 Zingiber officinale Nutrition 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- 239000012470 diluted sample Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 235000008397 ginger Nutrition 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 229940113124 polysorbate 60 Drugs 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229960001285 quercetin Drugs 0.000 description 3
- 235000005875 quercetin Nutrition 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- 230000037394 skin elasticity Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229920002258 tannic acid Polymers 0.000 description 3
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 3
- 235000015523 tannic acid Nutrition 0.000 description 3
- 229940033123 tannic acid Drugs 0.000 description 3
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 3
- 230000037373 wrinkle formation Effects 0.000 description 3
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 2
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 235000000665 Lycianthes asarifolia Nutrition 0.000 description 2
- 241000866517 Lycianthes asarifolia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 2
- 241000234314 Zingiber Species 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000272161 Charadriiformes Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 241000209205 Coix Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 244000019459 Cynara cardunculus Species 0.000 description 1
- 235000019106 Cynara scolymus Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 101710145505 Fiber protein Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001012968 Lychnis wilfordii Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010027146 Melanoderma Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 241001505935 Phalaenopsis Species 0.000 description 1
- 240000008154 Piper betle Species 0.000 description 1
- 235000008180 Piper betle Nutrition 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 244000060492 Silene coronaria Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 101710147108 Tyrosinase inhibitor Proteins 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 235000016520 artichoke thistle Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- BQYJATMQXGBDHF-UHFFFAOYSA-N difenoconazole Chemical compound O1C(C)COC1(C=1C(=CC(OC=2C=CC(Cl)=CC=2)=CC=1)Cl)CN1N=CN=C1 BQYJATMQXGBDHF-UHFFFAOYSA-N 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000012035 limiting reagent Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 235000019449 other food additives Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 동자꽃 추출물을 포함하는 특정 용도의 조성물에 관한 것이다The present invention relates to a composition of a specific use comprising a flower of a flower
Description
본 발명은 동자꽃 추출물을 포함하는 특정 용도의 조성물에 관한 것이다.
The present invention relates to a composition for a specific use comprising a flower of a flower of the genus.
최근 외모에 대한 관심이 높아지면서 피부노화를 지연시키고 예방하기 위한 연구가 활발하게 진행되고 있다. 그 중에서 주름과 미백에 대한 관심이 증가하면서 탄력있고 밝은 피부를 유지 및 개선하기 위해 후천적으로 높은 관심과 노력에 따라 개선 될수 있는 화장품의 필요성이 절실해 지고 있다.Recently, as interest in appearance has increased, researches for delaying and preventing skin aging have been actively conducted. Among them, the interest in wrinkles and whitening is increasing, and the necessity of cosmetics which can be improved according to the high interest and efforts to acquire the resilient and bright skin is urgently needed.
현재, 주름 개선 화장료로는 레티노이드, 아데노신, 동물 태반 유래 단백질, 클로렐라 추출물, 빈랑자 추출물 등이 알려져 있으나, 레티놀은 콜라겐 합성을 촉진하여 엘라스타아제 효소를 저해하는 물질이지만 불안정하고 피부 적용 시에 자극, 발작 등의 안전성 문제로 사용량의 제한이 있으며, 클로렐라 추출물 등은 효과가 미미하여 실질적으로 피부 주름 개선효과를 기대하기가 어렵다는 제한이 있다.
At present, retinoids, adenosine, animal placenta-derived proteins, chlorella extract, and bingo extract are known as wrinkle-improving cosmetics, but retinol is a substance that inhibits elastase enzyme by promoting collagen synthesis, but is unstable, , Seizures, etc., and there is a limitation in that it is difficult to expect an effect of substantially improving the wrinkles of the skin because chlorella extract has a small effect.
본 발명의 목적은 천연 유래 물질을 유효성분으로 포함하는 미백 또는 항노화 조성물을 제공하는 것이다.
It is an object of the present invention to provide a whitening or anti-aging composition comprising a naturally occurring substance as an active ingredient.
상기 목적을 달성하기 위해 본 발명은 동자꽃 추출물을 유효성분으로 포함하는 미백용 조성물을 제공한다. 본 발명은 또한 동자꽃 추출물을 유효성분으로 포함하는 항노화 조성물을 제공한다.
In order to attain the above object, the present invention provides a whitening composition comprising an extract of a flower of Aspergillus as an active ingredient. The present invention also provides an anti-aging composition comprising aspartame flower extract as an active ingredient.
본 발명의 조성물은 티로시나제 저해 효과와 엘라스타제 저해 효과를 가지는 동자꽃 식물의 추출물을 포함하여, 피부 미백 및 항노화 방지를 위해 유용하게 사용할 수 있다. 특히 본 발명의 조성물은 타이로시나제 저해제로 알려진 코직산과 동일한 농도로 사용시, 비슷하거나 우수한 효과를 나타내므로, 고가의 코직산을 대체할 수 있어서 경제적이다. 뿐만 아니라 본 발명의 조성물은 천연 식물로부터 얻어지는 추출물을 포함하여 친환경적이고, 장기간 사용시에도 내성이 발생할 확률이 거의 없으며, 저자극성이라는 장점이 있다.
The composition of the present invention can be usefully used for skin whitening and anti-aging prevention, including an extract of a flower bud plant having a tyrosinase inhibiting effect and an elastase inhibiting effect. In particular, the composition of the present invention shows similar or superior effects when used at the same concentration as kojic acid, which is known as a tyrosinase inhibitor, so that it is economical to replace expensive kojic acid. In addition, the composition of the present invention is environmentally friendly, including extracts obtained from natural plants, and is less likely to develop resistance even after long-term use, and has the advantage of being hypoallergenic.
도 1은 동자꽃 추출물의 지표성분 및 항산화 성분 분석을 확인한 결과이다.
도 2는 동자꽃 추출물이 엘라스타제의 활성을 억제하는지 여부를 살펴본 결과이다.
도 3은 동자꽃 추출물이 티로시나제의 활성을 억제하는지 여부를 살펴본 결과이다.
도 4는 시판 미백 물질로 사용되는 코직산과 동자꽃 추출물의 티로시나제에 대한 활성 억제 정도를 비교한 것이다.
도 5는 동자꽃 추출물의 DPPH 라디컬의 소거능을 확인한 결과이다. FIG. 1 shows the results of analysis of the indicator components and antioxidant components of the flower of the wild type.
FIG. 2 shows the result of examining whether or not the extract from the flower of the flower suppresses the activity of elastase.
FIG. 3 shows the result of examining whether or not the flower of the conifer of the present invention suppresses the activity of tyrosinase.
FIG. 4 is a graph comparing the degree of suppression of tyrosinase activity of kojic acid and coix flower extract used as a commercially available whitening agent.
FIG. 5 shows the results of confirming the scavenging ability of the DPPH radical of the cochlea extract.
본 발명은 일 관점에서, 동자꽃 추출물을 유효성분으로 포함하는, 미백용 조성물에 관한 것이다. In one aspect, the present invention relates to a composition for whitening comprising an extract of a plant extract as an active ingredient.
본 명세서에서 상기 "동자꽃 식물"은 한글명으로 동자꽃이라는 명칭을 포함하는 식물이라면 제한없이 포함할 수 있으며, 구체적으로 동자꽃, 가는동자꽃, 제비동자꽃 및 우단동자꽃으로 구성된 군에서 선택된 하나 이상의 식물을 포함할 수 있으나, 이에 제한되는 것은 아니다. In the present specification, the term "flower buds" may include any plants including the name of flower buds in Korean, and specifically includes flowers selected from the group consisting of flower buds, flowering buds, But are not limited thereto.
본 명세서에서 상기 "동자꽃 식물의 추출물"은 물, C1-C6 알콜, 및 이들이 조합으로 구성된 그룹에서 선택된 용매의 조추출물일 수 있다. 상기 C1-C6 알콜은 구체적으로 메탄올 또는 에탄올일 수 있다. 동자꽃 식물을 용매로 추출 시, 동자꽃 식물의 약 5 내지 15배 정도에 해당하는 용매를 가하여 추출하는 것이 바람직하며, 구체적으로 약 10 배의 용매를 가하여 추출하는 것이 바람직하나, 이에 한정되는 것은 아니다. 상기 추출은 가열 추출, 냉침 추출, 환류냉각 추출, 또는 초음파 추출 등이 이용될 수 있으며, 당업자에게 자명한 추출법이라면 제한이 없다. 상기 추출은 실온에서 수행할 수도 있으나, 보다 효율적인 추출을 위해서는 가온 조건 하에서 수행할 수 있으며, 바람직하게는 약 40 내지 100℃, 더욱 바람직하게는 약 80℃의 온도에서 추출할 수 있으나, 이에 한정되는 것은 아니다. 추출시간은 바람직하게는 약 2 내지 4시간, 더욱 바람직하게는 약 3 시간 동안 수행할 수 있으나 이에 한정되는 것은 아니며, 추출 용매 및 추출 온도 등의 조건에 따라 달라질 수 있다. 상기 추출은 활성성분을 보다 다량 수득하기 위해 1 회 이상 여러 번 추출할 수 있으며, 바람직하게는 1 내지 5회, 더욱 바람직하게는 3회 연속추출하여 합한 추출액을 이용할 수 있다.As used herein, the "extracts of flower plants" may be crude extracts of solvents selected from the group consisting of water, C 1 -C 6 alcohols, and combinations thereof. The C 1 -C 6 alcohol may specifically be methanol or ethanol. When the plant is extracted with a solvent, it is preferable to extract the plant by adding about 5 to 15 times as much solvent as the plant, and more preferably about 10 times the amount of the solvent, no. The extraction may be performed by heat extraction, cold extraction, reflux cooling extraction, ultrasonic extraction or the like, and there is no limitation as long as it is an extraction method that is obvious to a person skilled in the art. The extraction may be carried out at room temperature, but it may be carried out under heating at a temperature of about 40 to 100 ° C, more preferably about 80 ° C, for a more efficient extraction, It is not. The extraction time is preferably about 2 to 4 hours, more preferably about 3 hours, but it is not limited thereto and may be varied depending on conditions such as extraction solvent and extraction temperature. The extraction may be carried out one or more times several times to obtain a larger amount of the active ingredient, preferably 1 to 5 times, more preferably 3 times of continuous extraction.
본 명세서에서 동자꽃 식물 추출물은 상기와 같이 동자꽃 식물의 조추출물을 포함할 수 있고, 상기 조추출물을 극성이 낮은 유기 용매로 더욱 추출하여 얻어진 유기 용매의 가용성 분획물로서 포함할 수도 있다. 상기 유기 용매로는 헥산, 메틸렌클로라이드, 에틸 아세테이트, n-부탄올 등이 이용될 수 있으나, 이에 한정되는 것은 아니다. 상기의 방법으로 추출한 추출물 또는 그 추출물의 가용성 분획물은 그대로 사용할 수도 있으나, 여과 후 농축하여 엑기스 형태로 사용할 수 있으며, 농축 후 동결 건조하여 동결건조물의 형태로서 사용할 수 있다.In the present specification, the coniferous plant extract may contain crude extracts of the coniferous plants as described above, and may be included as a soluble fraction of the organic solvent obtained by further extracting the crude extract with an organic solvent having a low polarity. Examples of the organic solvent include, but are not limited to, hexane, methylene chloride, ethyl acetate, n-butanol, and the like. The extract or the soluble fraction of the extract may be used as it is, or may be used as an extract form by concentration after filtration, and may be used as a form of a lyophilizate by concentration and freeze-drying.
아울러 본 명세서에서 사용되는 동자꽃 식물은 초본의 지상부 또는 지하부의 일부 또는 전부, 예컨대 잎, 잔가지, 줄기, 뿌리 또는 종자를 이용할 수 있고, 구체적으로 뿌리를 이용할 수 있으나 이에 제한되는 것은 아니다.In addition, the coniferous plants used in the present invention may be part or all of the ground or underground portion of the herb such as leaves, twigs, stalks, roots or seeds, and may be roots, but is not limited thereto.
본 명세서에서 상기 "미백"은 피부를 하얗게 하는 화이트닝을 의미할 수 있고, 또는 검버섯, 기미, 색소 침착에 의한 흉터 등에서 색소 침착을 방지하고 개선함에 따라 피부톤을 투명하고 맑게 하는 것을 의미할 수 있다. 본 발명의 일 관점인 미백용 조성물에서, 동자꽃 추출물은 항산화 활성을 가지며, 티로시나제의 생성 및 활성을 억제 또는 저해시킬 수 있어서, 피부 미백 용도에 유용하게 사용할 수 있다. In the present specification, the term "whitening" may mean whitening whitening of the skin, or it may mean that the skin tone is transparent and clear as it prevents and improves pigmentation in scars due to black spot, spots and pigmentation. In the composition for whitening, which is one aspect of the present invention, the cochlea extract has an antioxidative activity and can inhibit or inhibit the production and activity of tyrosinase, and thus can be usefully used for skin whitening applications.
본 발명은 다른 관점에서, 동자꽃 식물의 추출물을 유효성분으로 포함하는, 항노화용 조성물에 관한 것이다. In another aspect, the present invention relates to a composition for anti-aging comprising an extract of a plant of Aspergillus as an active ingredient.
본 명세서에서 상기 "항노화"는 노화의 개선 또는 노화의 지연 등을 의미할 수 있다. 본 발명의 일 관점인 항노화용 조성물에서, 동자꽃 추출물은 항산화 활성을 가지므로, 세포의 노화를 가져오는 활성 산소를 저해할 수 있으므로, 세포의 산화 및 세포의 노화를 막을 수 있다. 구체적으로 본 발명의 일 관점인 항노화용 조성물은 엘라스타제의 생성 또는 활성을 억제할 수 있어서, 주름 생성을 억제하고 이미 생성된 주름을 개선할 수 있어서, 피부 탄력 개선 및 탄력 유지에 유용하게 사용할 수 있다. 이에 따라, 본 발명은 다른 관점에서, 동자꽃 식물의 추출물을 유효성분으로 포함하는 주름 생성 억제용, 주름 개선용 피부 탄력 개선용 또는 피부 탄력 유지용 조성물을 포함할 수 있다. As used herein, the term " anti-aging "may mean improvement in aging or delay in aging. In the anti-aging composition which is one aspect of the present invention, the extract of Asteraceae has an antioxidative activity, which can inhibit active oxygen that causes cell senescence, thereby preventing oxidation of cells and aging of cells. Specifically, the anti-aging composition, which is one aspect of the present invention, can inhibit the production or activity of elastase, thereby suppressing wrinkle formation and improving already formed wrinkles, . Accordingly, in another aspect, the present invention may include a composition for suppressing wrinkle formation, for improving skin elasticity for wrinkle improvement, or for maintaining skin elasticity, which comprises an extract of a plant of the same species as an active ingredient.
본 발명의 일 관점인 미백용 조성물에 있어서, 상기 조성물은 티로시나제의 생성 또는 티로시나제의 활성을 억제할 수 있다. 본 발명의 일 관점인 미백용 조성물은 멜라닌 생합성에 관여하는 티로시나제 (tyrosinase)의 생성량 자체를 줄이거나, 또는 정상적으로 생성된 티로시나제의 활성을 억제하여 제 기능을 할 수 없도록 하여 피부 미백에 유용하다. 본 발명의 일 관점인 미백용 조성물은 또한, 상기와 같이 티로시나제 자체에 대한 효과 뿐 아니라, 티로시나제의 생성 및 그 활성에 관여하는 전 단계 (up-stream)의 효소, 단백질 등의 생성량 및 활성을 조절할 수 있어서 유용하다. In the composition for whitening, which is one aspect of the present invention, the composition can inhibit the production of tyrosinase or the activity of tyrosinase. The composition for whitening, which is one aspect of the present invention, is useful for skin whitening by reducing the production amount of tyrosinase per se which is involved in melanin biosynthesis, or by inhibiting the activity of normally produced tyrosinase, thereby failing to function. The composition for whitening, which is one aspect of the present invention, is also capable of controlling not only the effect on the tyrosinase itself but also the production and activity of up-stream enzymes and proteins involved in the production of tyrosinase and its activity And is useful.
본 발명의 일 관점인 항노화용 조성물에 있어서, 상기 조성물은 주름 생성을 억제하거나 또는 주름을 개선할 수 있다. In the anti-aging composition which is one aspect of the present invention, the composition can suppress wrinkle formation or improve wrinkles.
본 발명의 일 관점인 항노화용 조성물에 있어서, 상기 조성물은 엘라스타제의 생성 또는 엘라스타제의 활성을 억제할 수 있다. 엘라스타제(elastase)는 피부 탄력을 유지해주는 동물 결합조직의 불용성 탄성섬유단백질인 엘라스틴(elastin)을 분해하는 유일한 분해효소로 알려져 있다(Wiedow, O., Schroder, J. M., E. J. Biol. Chem., 265(5), p14791, 1990). 본 발명의 일 관점인 항노화용 조성물은 이러한 엘라스타제의 생성량 자체를 줄이거나, 또는 정상적으로 생성된 엘라스타제의 활성을 억제하여 제 기능을 할 수 없도록 하여 노화 억제, 노화 지연 등에 유용하다. 본 발명의 일 관점인 항노화용 조성물은 또한, 상기와 같이 엘라스타제 자체에 대한 효과 뿐 아니라, 엘라스타제 의 생성 및 그 활성에 관여하는 전 단계 (up-stream)의 효소, 단백질 등의 생성량 및 활성을 조절할 수 있어서 유용하다. In the anti-aging composition which is one aspect of the present invention, the composition can inhibit the production of elastase or the activity of elastase. Elastase is known to be the only degrading enzyme that degrades elastin, an insoluble elastic fiber protein of animal connective tissue that maintains skin elasticity (Wiedow, O., Schroder, JM, EJ Biol. Chem. 265 (5), p14791, 1990). The anti-aging composition, which is one aspect of the present invention, is useful for suppressing aging, retarding aging, etc., by reducing the amount of the elastase produced per se or by inhibiting the activity of the normally produced elastase and preventing its function. The anti-aging composition, which is one aspect of the present invention, can be used not only for the effect on the elastase itself as described above, but also for the production of elastase and the amount of the up- And activity.
본 발명의 일 관점인 조성물에 있어서, 상기 조성물은 화장료 조성물 또는 건강식품 조성물일 수 있다. In one aspect of the invention, the composition may be a cosmetic composition or a health food composition.
본 발명에 따른 화장료 조성물은 국소 적용에 적합한 모든 제형으로 제공될 수 있다. 예를 들면, 용액, 수상에 유상을 분산시켜 얻은 에멀젼, 유상에 수상을 분산시켜 얻은 에멀젼, 현탁액, 고체, 겔, 분말, 페이스트, 포말(foam) 또는 에어로졸 조성물의 제형으로 제공될 수 있다. 이러한 제형의 조성물은 당해 분야의 통상적인 방법에 따라 제조될 수 있다.The cosmetic composition according to the present invention may be provided in all formulations suitable for topical application. For example, it may be provided as a solution, an emulsion obtained by dispersing an oil phase in an aqueous phase, an emulsion obtained by dispersing an oil phase in water, a suspension, a solid, a gel, a powder, a paste, a foam or an aerosol composition. Compositions of such formulations may be prepared according to conventional methods in the art.
본 발명에 따른 화장료 조성물은 상기한 물질 이외에 주 효과를 손상시키지 않는 범위 내에서, 바람직하게는 주 효과에 상승 효과를 줄 수 있는 다른 성분들을 포함할 수 있다. 또한 본 발명에 따른 화장료 조성물은 보습제, 에몰리언트제, 자외선 흡수제, 방부제, 살균제, 산화 방지제, pH 조정제, 유기 및 무기 안료, 향료, 냉감제 또는 제한제를 더 포함할 수 있다. 상기 성분의 배합량은 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 당업자가 용이하게 선정 가능하며, 그 배합량은 조성물 전체 중량을 기준으로 0.01 내지 5 중량%, 구체적으로 0.01 내지 3 중량%일 수 있다.The cosmetic composition according to the present invention may contain, in addition to the above-mentioned substances, other ingredients which can give a synergistic effect to the main effect, so long as they do not impair the main effect. The cosmetic composition according to the present invention may further comprise a moisturizing agent, an emollient agent, an ultraviolet absorber, an antiseptic, a bactericide, an antioxidant, a pH adjuster, an organic and inorganic pigment, a fragrance, a cold agent or a limiting agent. The compounding amount of the above components can be easily selected by those skilled in the art within a range not to impair the objects and effects of the present invention. The amount thereof may be 0.01 to 5% by weight, specifically 0.01 to 3% by weight, have.
상기 조성물은 이를 포함하는 드링크제, 발효유, 치즈, 요구르트, 주스, 생균제제 및 건강보조식품 등으로 가공될 수 있으며, 그 외 다양한 식품 첨가제의 형태로 사용될 수 있다. The composition may be processed into a drink, fermented milk, cheese, yogurt, juice, probiotic agent, and health supplement food or the like, and may be used in various other food additives.
일실시예에서 상기 조성물은, 본 발명이 목적으로 하는 주 효과를 손상시키지 않는 범위 내에서 주 효과에 상승 효과를 줄 수 있는 다른 성분 등을 함유할 수 있다. 예를 들어, 물성 개선을 위하여 향료, 색소, 살균제, 산화방지제, 방부제, 보습제, 점증제, 무기염류, 유화제 및 합성 고분자 물질 등의 첨가제를 더 포함할 수 있다. 그 외에도, 수용성 비타민, 유용성 비타민, 고분자 펩티드, 고분자 다당 및 해초 엑기스 등의 보조 성분을 더 포함할 수도 있다. 상기 성분들은 제형 또는 사용 목적에 따라서 당업자가 어려움 없이 적의 선정하여 배합할 수 있으며, 그 첨가량은 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 선택될 수 있다. In one embodiment, the composition may contain other ingredients or the like that can give synergistic effects to the main effect within a range that does not impair the intended main effect of the present invention. For example, additives such as perfume, coloring agent, bactericide, antioxidant, preservative, moisturizing agent, thickening agent, inorganic salt, emulsifier and synthetic polymer substance may be further added for improvement of physical properties. In addition, it may further contain auxiliary components such as water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymeric polysaccharides and seaweed extract. The above components may be mixed and selected without difficulty by those skilled in the art depending on the purpose of formulation or use, and the amount thereof may be selected within a range that does not impair the objects and effects of the present invention.
본 발명에 따른 조성물의 제형은 용액, 유화물, 점성형 혼합물, 타블렛, 분말 등의 다양한 형태일 수 있으며, 이는 단순 음용, 주사 투여, 스프레이 방식 또는 스퀴즈 방식 등의 다양한 방법으로 투여될 수 있다. The composition according to the present invention may be in various forms such as a solution, an emulsion, a viscous mixture, a tablet, a powder, etc., and may be administered by various methods such as simple drinking, injection administration, spraying or squeezing.
본 발명의 일 관점인 조성물에 있어서, 상기 조성물은 약학 조성물일 수 있다. In one aspect of the invention, the composition may be a pharmaceutical composition.
본 발명에 따른 조성물을 의약품에 적용할 경우에는, 상기 조성물을 유효성분으로 하여 상용되는 무기 또는 유기의 담체를 가하여 고체, 반고체 또는 액상의 형태로 경구 투여제 혹은 비경구 투여제로 제제화 할 수 있다.When the composition according to the present invention is applied to medicines, it may be formulated into an oral or parenteral dosage form in the form of solid, semi-solid or liquid by adding an inorganic or organic carrier to the composition as an active ingredient.
상기 경구 투여를 위한 제재로서는 정제, 환제, 과립제, 캡슐제, 산제, 세립제, 분제, 유탁제, 시럽제, 펠렛제 등을 들 수 있다. 또한, 상기 비경구 투여를 위한 제재로는 주사제, 점적제, 연고, 로션, 스프레이, 현탁제, 유제, 좌제 등을 들 수 있다. 본 발명의 유효성분을 제제화하기 위해서는 상법에 따라서 실시하면 용이하게 제제화할 수 있으며 계면활성제, 부형제, 착색료, 향신료, 보존료, 안정제, 완충제, 현탁제, 기타 상용하는 보조제를 적당히 사용할 수 있다.Examples of the agent for oral administration include tablets, pills, granules, capsules, powders, fine granules, powders, emulsions, syrups and pellets. Examples of the parenteral administration agent include injections, drops, ointments, lotions, sprays, suspensions, emulsions, suppositories, and the like. In order to formulate the active ingredient of the present invention, it can be easily formulated according to the conventional method. Surfactants, excipients, coloring agents, spices, preservatives, stabilizers, buffering agents, suspending agents and other adjuvants can be suitably used.
본 발명에 따른 상기 약학 조성물은 경구, 비경구, 직장, 국소, 경피, 정맥 내, 근육 내, 복강 내, 피하 등으로 투여될 수 있다. The pharmaceutical composition according to the present invention may be administered orally, parenterally, rectally, topically, transdermally, intravenously, intramuscularly, intraperitoneally, subcutaneously and the like.
본 발명의 약학 조성물의 유효 성분은 투여 받을 대상의 연령, 성별, 체중, 병리 상태 및 그 심각도, 투여 경로 또는 처방자의 판단에 따라 달라질 것이다. 이러한 인자에 기초한 적용량 결정은 당업자의 수준 내에 있으며, 이의 1일 투여 용량은 예를 들어 0.1㎍/kg/일 내지 100㎍/kg/일, 보다 구체적으로는 5 ㎍/kg/일 내지 50 ㎍/kg/일이 될 수 있으나, 이에 제한되는 것은 아니다.The effective ingredients of the pharmaceutical composition of the present invention will vary depending on the age, sex, weight, pathological condition and severity of the subject to be treated, administration route or judgment of the prescriber. Determination of the amount of application based on these factors is within the level of ordinary skill in the art and its daily dose is, for example, from 0.1 μg / kg / day to 100 μg / kg / day, more specifically from 5 μg / kg / day to 50 μg / kg / day. < / RTI >
본 발명의 일 관점이 조성물에 있어서, 상기 조성물은 동자꽃 식물의 추출물을 조성물 총 중량에 대하여 0.00001-20.0중량％로 포함할 수 있다. 본 발명의 일 관점인 조성물이 상기 동자꽃 식물 추출물을 0.00001% 미만으로 함유하면 미백 또는 주름 개선 등에 미치는 효과가 미미하며, 20%를 초과하여 함유하는 경우 다른 조성에 영향을 미쳐서 적절하지 않다. 상기와 같은 관점에서, 상기 조성물은 동자꽃 식물 추출물을 조성물 총 중량에 대하여 0.00005 내지 18 중량%, 0.0001 내지 16 중량%, 0.0005 내지 14 중량%, 0.001 내지 12 중량%, 0.005 내지 10 중량% 또는 0.01 내지 8 중량%로 포함할 수 있다. 더 구체적으로, 상기 조성물은 동자꽃 식물의 추출물을 조성물 총 중량에 대하여 0.01 내지 10.0중량%, 또는 0.1 - 5.0 중량%로 함유할 수 있다. In one aspect of the present invention, the composition may comprise from 0.00001 to 20.0% by weight, based on the total weight of the composition, of an extract of a flower bud plant. If the composition contains less than 0.00001% of the plant extract of the present invention, the effect on whitening or wrinkle improvement is insignificant. If the composition contains more than 20%, it is not suitable because it affects other compositions. In view of the above, the composition may contain 0.00005 to 18 wt.%, 0.0001 to 16 wt.%, 0.0005 to 14 wt.%, 0.001 to 12 wt.%, 0.005 to 10 wt.% Or 0.01 By weight to 8% by weight. More specifically, the composition may contain from 0.01 to 10.0 wt.%, Or from 0.1 to 5.0 wt.%, Based on the total weight of the composition, of an extract of the equine flower plant.
본 발명의 일 관점이 조성물에 있어서, 상기 동자꽃 식물의 추출물은 동자꽃 식물의 뿌리 추출물일 수 있다. In one aspect of the present invention, the composition of the present invention may be a root extract of a conifer plant.
본 발명의 일 관점이 조성물에 있어서, 상기 동자꽃 식물은 동자꽃, 가는동자꽃, 제비동자꽃 및 우단동자꽃으로 구성된 군에서 선택된 하나 이상의 식물을 포함할 수 있다. 본 명세서에서 상기 동자꽃은 리히니스 코그나타 (Lychnis cognate)일 수 있고, 상기 가는동자꽃은 리히니스 키우시아나 (Lychnis kiusiana)일 수 있으며, 상기 제비동자꽃은 리히니스 윌포디(Lychnis wilfordii)일 수 있다. 아울러, 상기 우단동자꽃은 리히니스 코로나리아 (Lychnis coronaria)일 수 있다.
One aspect of the present invention is a composition, wherein the co-flower plants may comprise one or more plants selected from the group consisting of cochlea, goat, blossom, and velvet. In the present specification, the coniferous flower is referred to as Lychnis cognate , and the migratory flower may be Lychnis kiusiana ), and the plover may be Lychnis wilfordii . In addition, the velvet hawthorn flowers were identified as Lychnis coronaria .
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.
Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for illustrating the present invention and that the scope of the present invention is not construed as being limited by these embodiments.
[[ 실시예Example ]]
동자꽃 추출물의 제조Production of flower buds
동자꽃(Lychnis cognate) 뿌리를 산지에서 채취하여 건조 중량 100g씩을 각각 플라스크에 넣고 70% 에탄올 (Ethyl alcohol) 1ℓ로 1일간 냉침하여 추출한 후, 여과하여 찌꺼기를 제거함으로써 동자꽃 뿌리 추출물을 제조하였다.
The bush flower ( Lychnis cognate roots were taken from the mountain and 100 g of dry weight was added to each flask. The mixture was extracted by cooling with 1 L of 70% ethanol (Ethyl alcohol) for 1 day, and then filtered to remove debris.
[[ 비교예Comparative Example 1] One]
생강나무 추출물의 제조 Manufacture of ginger tree extract
생강나무 잎을 산지에서 채취하여 건조 중량 100g씩을 각각 플라스크에 넣고 70% 에탄올 (Ethyl alcohol) 1ℓ로 1일간 냉침하여 추출한 후, 여과하여 찌꺼기를 제거함으로써 생강나무 잎 추출물을 제조하였다.
Ginger leaves were harvested from the mountains and 100 g of dry weight was added to each flask. The extracts were extracted by cooling with 1 L of 70% ethanol (Ethyl alcohol) for 1 day and then filtered to remove ginger leaves.
[[ 비교예Comparative Example 2] 2]
멸가치Wasting value 추출물의 제조 Preparation of extract
멸가치를 산지에서 채취하여 멸가치 뿌리, 꽃대 및 잎 각각을 건조 중량 100g씩 플라스크에 넣고 70% 에탄올 (Ethyl alcohol) 1ℓ로 1일간 냉침하여 추출한 후, 여과하여 찌꺼기를 제거함으로써 멸가치 뿌리 추출물 (비교예 2-1), 멸가치 꽃대 추출물 (비교예 2-2) 및 멸가치 잎 추출물 (비교예 2-3) 각각을 제조하였다.
The value of the decay was taken from the mountain, and the root of the decaying value, the peduncle and the leaf were put into a flask with a dry weight of 100 g, and the mixture was extracted by cooling with 1 L of 70% Ethyl alcohol for 1 day and then filtered to remove the residue. (Comparative Example 2-1), a decaying phalaenopsis extract (Comparative Example 2-2), and a decanter leaf extract (Comparative Example 2-3) were prepared.
[[ 비교예Comparative Example 3] 3]
빈랑자Bingo 추출물의 제조 Preparation of extract
빈랑자(빈랑 나무의 열매)를 산지에서 채취하여 건조 중량 100g씩을 각각 플라스크에 넣고 70% 에탄올 (Ethyl alcohol) 1ℓ로 1일간 냉침하여 추출한 후, 여과하여 찌꺼기를 제거함으로써 빈랑자 추출물을 제조하였다.
Bingulja (fruit of the betel) was collected from the mountain and 100 g of dry weight was added to each flask. The extract was extracted by cooling with 1 L of 70% ethanol (Ethyl alcohol) for 1 day and then filtered to remove debris.
[[ 비교예Comparative Example 4] 4]
산겨릅Live 나무 추출물의 제조 Manufacture of tree extracts
산겨릅나무(=벌나무)를 산지에서 채취하여 잎 및 줄기 100g씩을 각각 플라스크에 넣고 70% 에탄올 (Ethyl alcohol) 1ℓ로 1일간 냉침하여 추출한 후, 여과하여 찌꺼기를 제거함으로써 산겨릅나무의 잎 추출물 (비교예 4-1) 및 산겨릅나무의 줄기 추출물 (비교예 4-2)을 제조하였다.100 g of leaf and stem were placed in a flask, and the mixture was extracted by cooling with 1 L of 70% ethanol (Ethyl alcohol) for 1 day and then filtered to remove the leaves. Comparative Example 4-1) and a stem extract of an acid elet (Comparative Example 4-2) were prepared.
[[ 실험예Experimental Example 1] One]
ABTSABTS 온라인항산화 Online antioxidant HPLCHPLC 를 활용한 지표성분 및 항산화 성분 분석 Analysis of surface and antioxidant components
상기 실시예 1에서 제조한 동자꽃 뿌리 추출물은 메탄올로 용해하여 0.45 μm PVDF syringe filter(Whatman, Maidstone, England)를 통과시킨 다음 온라인 항산화 HPLC 장치 (1200 series, Agilent Technologies, Santa Clara, CA, USA)를 사용하여 지표성분 및 항산화 성분 분석하였다. 컬럼은 Hydrosphere C18 column (4.6 × 150 mm), 검출기는 UV(280 nm), 이동상은 HPLC grade용 아세토니트릴 (A)과 물 (B)을 0~10분, 10% A; 10~30분 10-100% A 의 조건으로 linear gradient하였으며, 유량은 1.0 mL/분 (아세토나이트릴, 물)과 0.5 mL/분 (ABTS 용액)으로 하였고, 시료주입량은 10 μL로 하였다. 이 때 동자꽃 뿌리 추출물의 지표성분 및 항산화 성분의 프로파일은 280nm 크로마토그램에서 포지티브 피크로 측정하여 나타내었고 각 피크에 대한 항산화 활성은 734nm 크로마토그램에서 네거티브 피크로 측정하여 도 1에 나타내었다.The supernatant obtained in Example 1 was dissolved in methanol, passed through a 0.45 μm PVDF syringe filter (Whatman, Maidstone, England) and then subjected to on-line antioxidant HPLC (1200 series, Agilent Technologies, Santa Clara, Were used to analyze the surface and antioxidant components. The column was equipped with a Hydrosphere C18 column (4.6 × 150 mm), the detector was UV (280 nm), the mobile phase was acetonitrile (A) and water (B) for HPLC grade for 0-10 minutes, 10% A; The flow rate was 1.0 mL / min (acetonitrile, water) and 0.5 mL / min (ABTS solution) and the sample injection volume was 10 μL for 10-30 minutes at 10-100% A. The profile and antioxidant component profiles of the root extract of Panax notoginscholus were measured by a positive peak at 280 nm chromatogram, and the antioxidative activity against each peak was measured with a negative peak at 734 nm chromatogram and shown in FIG.
도 1에 의해, 피크 1은 트리터페노이드계의 사포닌의 일종이고, 피크 2와 3은 항산화 활성을 가지는 페놀릭 화합물로 확인되므로, 본 발명 조성물의 유효성분인 동자꽃 추출물은 항산화 물질을 포함함을 확인할 수 있었다.
1,
[[ 실험예Experimental Example 2] 2]
동자꽃 추출물의 Flower of a flower 엘라스타제Elastase 활성 억제 실험 Activity inhibition experiment
상기 실시예에서 수득한 동자꽃 추출물의 엘라스타제 활성 저해 작용을 아래와 같이 살펴 보았다. 양성 대조군으로는 주름 개선 용도를 가지는 것으로 알려져 있는 생강나무 잎 추출물 (대한민국 공개특허 제 10-2010-0072398호, 비교예 1), 멸가치 추출물 (대한민국 공개특허 제10-2011-0087363호, 비교예 2-1 내지 2-3), 빈랑자 추출물 (대한민국 공개특허 제1999-0058669호, 비교예 3), 산겨릅나무 추출물 (대한민국 공개특허 제10-2012-0033552호, 비교예 4-1 및 4-2)를 이용하였다. 각각의 추출물은 50ppm 의 농도로 하여 사용하였다. The inhibition of elastase activity of the flower buds obtained in the above Examples was examined as follows. As a positive control group, ginger leaf extract (Korean Patent Laid-Open No. 10-2010-0072398, Comparative Example 1), wilt value extract (Korean Patent Publication No. 10-2011-0087363, Comparative Example 2-1 to 2-3), bingoja extract (Korea Patent Publication No. 1999-0058669, Comparative Example 3), acid elek extract (Korea Patent Publication No. 10-2012-0033552, Comparative Examples 4-1 and 4 -2) was used. Each extract was used at a concentration of 50 ppm.
먼저, 완충용액(0.267M Tris 용액을 0.267M 염산용액으로 pH 8.0이 되도록 조정) 1ml에 엘라스타아제 기질 Succ-Ala-Ala-p-nitroanilide(시그마사, 미국)을 4mg 넣어 섞었다(8.8mM 기질용액이 됨). 다음으로 효소인 돼지 췌장 엘라스타아제 (Porcine Pancreatic Elastase, 표준품; 시그마사, 미국)를 완충용액으로 10㎍/ml의 농도로 만든다. 이렇게 준비된 기질용액과 각각 의 시료를 섞은 후, 효소용액을 첨가하여 25 ℃에서 15분간 반응시켰다. 반응 후, 405nm에서 흡광도를 측정하였다. 이때 음성대조군은 시료 대신 버퍼를 사용하였고 블랭크(blank)는 버퍼와 샘플 녹인 용매만을 사용하였다. 엘라스타아제 활성 억제율은 하기 수학식 1을 이용하여 계산하였으며, 그 결과를 도 2에서 도표화하여 나타내었다. .
First, 4 mg of Elastase substrate Succ-Ala-Ala-p-nitroanilide (Sigma, USA) was added to 1 ml of a buffer solution (0.267 M Tris solution adjusted to pH 8.0 with 0.267 M hydrochloric acid solution) Substrate solution). Next, the enzyme Porcine Pancreatic Elastase (Sigma, USA) is buffered to a concentration of 10 μg / ml. After mixing the prepared substrate solution and each sample, the enzyme solution was added and reacted at 25 ° C for 15 minutes. After the reaction, the absorbance was measured at 405 nm. In this case, the negative control was a buffer instead of the sample, and the blank was a buffer and a sample-dissolved solvent alone. The inhibition rate of the elastase activity was calculated using the following equation (1), and the results are tabulated in FIG. .
[수학식 1][Equation 1]
엘라스타아제 활성 억제율(%) = [(음성대조군의 흡광도 - 블랭크 흡광도)-(각 실험군 시료의 흡광도 - 블랭크 흡광도)] / (음성대조군의 흡광도 - 블랭크 흡광도) X 100
Elastase activity inhibition rate (%) = [(absorbance of negative control - blank absorbance) - (absorbance of each sample group - blank absorbance)] / (absorbance of negative control - blank absorbance)
그 결과, 동자꽃 추출물의 엘라스타제 활성 억제효과가 가장 우수함을 확인할 수 있었다.
As a result, it was confirmed that the suppression of elastase activity was the most excellent.
[[ 실험예Experimental Example 3] 3]
동자꽃 추출물의 티로시나아제 활성 억제 실험-1Studies on inhibition of tyrosinase activity of flower buds
실시예 1에서 수득된 동자꽃 추출물과의 티로시나제 활성 억제 작용을 아래와 같이 살펴 보았다. 양성 대조군으로 미백 효과를 가지는 것으로 알려져 있는 생강나무 잎 추출물 (대한민국 공개특허 제 10-2010-0072398호, 비교예 1) 및 산겨릅나무 추출물 (대한민국 공개특허 제10-2012-0033552호, 비교예 4-1 및 4-2)을 이용하였다. 각각의 추출물은 50ppm 의 농도로 하여 사용하였다. 각각의 추출물 시료와 0.1M 인산나트륨 완충액(pH 6.8) 210㎕ 및 1.5mM L-DOPA 용액 40㎕를 96웰 플레이트에 넣은 후, 37℃에서 10분간 온도를 유지시켰다. 그 후 머시룸티로시나제(1500unit/mL) 20㎕를 첨가하여 37℃에서 10분간 반응시킨 후, 492㎚에서 흡광도를 측정하여 티로시나제에 대한 저해율을 측정하였다. 티로시나아제는 감자나 버섯으로부터 정제되는 효소로서, 본 실험에서는 버섯류로부터 추출한 시그마(Sigma)사의 것을 사용하였다. 이때 음성대조군은 시료 대신 버퍼를 사용하였고 블랭크(blank)는 버퍼와 샘플 녹인 용매만을 사용하였다. 티로시나아제 활성 억제율은 하기 수학식 2를 이용하여 계산하였으며, 그 결과를 도 3에서 도표화하여 나타내었다.
The inhibitory activity of tyrosinase activity with the coniferous flower extract obtained in Example 1 was examined as follows. A ginger leaf extract (Korean Patent Laid-Open No. 10-2010-0072398, Comparative Example 1) and an artichoke extract (Korean Patent Laid-Open No. 10-2012-0033552, Comparative Example 4 -1 and 4-2) were used. Each extract was used at a concentration of 50 ppm. 210 μl of 0.1 M sodium phosphate buffer (pH 6.8) and 40 μl of a 1.5 mM L-DOPA solution were placed in a 96-well plate, and the temperature was maintained at 37 ° C. for 10 minutes. Subsequently, 20 μl of mercurial tyrosinase (1500 units / mL) was added, reacted at 37 ° C. for 10 minutes, and the absorbance at 492 nm was measured to determine the inhibition rate against tyrosinase. Tyrosinase is an enzyme purified from potato or mushroom. In this experiment, Sigma (Sigma) extracted from mushrooms was used. In this case, the negative control was a buffer instead of the sample, and the blank was a buffer and a sample-dissolved solvent alone. The inhibition rate of tyrosinase activity was calculated using the following equation (2), and the results are tabulated in FIG.
[수학식 2]&Quot; (2) "
티로시나아제 활성 억제율(%) = [(음성 대조군의 흡광도 - 블랭크 흡광도)-(실험군 시료의 흡광도 - 블랭크 흡광도)] / (음성 대조군의 흡광도 - 블랭크 흡광도) X 100
(%) = [(Absorbance of negative control - blank absorbance) - (absorbance of test sample - blank absorbance)] / (absorbance of negative control - blank absorbance)
그 결과 (도 3), 동자꽃 추출물의 티로시나제 억제효과가 가장 우수함을 확인할 수 있었다.
As a result (FIG. 3), it was confirmed that the tyrosinase inhibiting effect of the flower of the wild type was the best.
[[ 실험예Experimental Example 4] 4]
동자꽃 추출물의 티로시나아제 활성 억제 실험-2Studies on the inhibition of tyrosinase activity of flower buds-2
실험예 3과 동일한 방법으로 양성 대조군만을 코직산(Sigma, USA)으로 변경하여 동자꽃 추출물과 티로시나제 억제효과를 비교해 보았다 (도 4). 그 결과, 당업계에서 티로시나제의 저해제로 알려진 코직산과 비교하여 동자꽃 추출물이 비슷하거나 우수한 효과를 나타냄을 확인할 수 있었다.
In the same manner as in Experimental Example 3, only the positive control group was changed to kojic acid (Sigma, USA), and the inhibition effect of tyrosinase inhibition was compared (Fig. 4). As a result, it was confirmed that the extracts of the plant extracts exhibit similar or superior effects to kojic acid, which is known as an inhibitor of tyrosinase in the art.
[[ 실험예Experimental Example 5] 5]
동자꽃 추출물의 Flower of a flower 라디칼Radical 소거 능력 - Scraping ability - DPPHDPPH 라디칼Radical 포집Capture 실험 ( Experiment ( DPPHDPPH radicalradical scavenging scavenging testtest ))
유기 용매에 녹인 DPPH(2,2-diphenyl-1-picrylhydrazyl) 라디칼은 515nm에서 최대 흡광도를 가지게 되는데, 항산화 물질은 DPPH 라디칼을 소거하여 고유의 색을 잃고 투명하게 변화시킨다. DPPH (2,2-diphenyl-1-picrylhydrazyl) radicals dissolved in organic solvents have the maximum absorbance at 515 nm. Antioxidants dissolve DPPH radicals and lose their intrinsic color and change their transparency.
DPPH 라디칼 포집의 측정을 위하여 실시예와 같은 과정으로 추출한 동자꽃 뿌리 추출물과 양성 대조군으로 비타민E의 유도체인 트롤록스(Sigma, USA)를 각각 최종농도 10ppm, 20ppm, 50ppm씩 농도를 조절하여 항산화능을 측정하였다. 각각의 희석한 시료와 에탄올을 96-웰에 넣은 후 DPPH 라디칼을 첨가하여 30분간 반응시켰다. 그 후, 515nm에서 라디칼 소거능을 측정하여, 소거능을 %로 표시하였다. 이때 대조군은 시료 대신 샘플녹인 용매인 에탄올과 ABTS 라디칼을 첨가하여 사용하였고 블랭크(blank)는 샘플 녹인 용매인 에탄올만을 사용하였다. 상기 실험군과 대조군에 대한 흡광도 측정 후, 하기 수학식 3을 이용하여 자유라디칼 소거활성 효과를 구하여 그 결과를 하기 도 5에 기재하였다.
For the measurement of DPPH radical scavenging activity, roots extracts of roots extracted with the same procedure as the example were used and positive control group, Trolox (Sigma, USA), a derivative of vitamin E, was used to control concentrations of 10 ppm, Were measured. Each diluted sample and ethanol were placed in a 96-well plate, and DPPH radicals were added to react for 30 minutes. Thereafter, the radical scavenging ability was measured at 515 nm, and the scavenging activity was expressed in%. At this time, in the control group, ethanol and ABTS radicals were used as a sample dissolving solvent instead of the sample, and only blank ethanol was used as a blank sample. After measuring the absorbance of the test group and the control group, the free radical scavenging activity was determined using the following equation (3), and the results are shown in FIG.
[수학식 3]&Quot; (3) "
DPPH 라디칼소거효과(%) = [(대조군의 흡광도 - 블랭크 흡광도)-(실험군 시료의 흡광도 - 블랭크 흡광도)] / (대조군의 흡광도 - 블랭크 흡광도) X 100
DPPH radical scavenging effect (%) = [(absorbance of control group - blank absorbance) - (absorbance of test sample - blank absorbance)] / (absorbance of control group - blank absorbance)
그 결과, 본 발명의 활성성분인 동자꽃 추출물이 시판 비타민E의 유도체인 트롤록스보다는 미약하지만 DPPH 라디컬의 소거능을 가지는 것으로 확인되어 항산화능을 가지는 것으로 확인되었다. 아울러 이에 따라, 본 발명의 활성성분인 동자꽃 추출물은 주로 항산화 경로와 별도인 미백 및 주름개선 경로에 의해 피부 미백 및 주름 개선을 통한 항노화 효과를 가져오는 것을 확인할 수 있었다.
As a result, it was confirmed that the extract of the present invention, which is an active ingredient of the present invention, is weaker than Trolox, a derivative of commercial vitamin E, but has a scavenging ability of DPPH radical and thus has antioxidant ability. In addition, it has been confirmed that the extract of the flower of the present invention, which is an active ingredient of the present invention, has anti-aging effect through whitening and wrinkle improvement by whitening and wrinkle improving pathways which are separate from antioxidative pathways.
[[ 실험예Experimental Example 6] 6]
동자꽃 추출물 내 총 폴리페놀 함량 측정Total polyphenol content in flower bud extract
실시예에 의하여 얻어진 동자꽃 추출물 시료 10mg을 증류수에 희석하였다. 희석한 시료 20ul를 96-웰 플레이트에 넣고 다시 60ul의 증류수를 넣어 80ul가 되도록 희석하였다. 여기에 20ul의 폴린-치오칼텐 시약(Folin-Ciocalten reagent)을 첨가하여 5분동안 반응시킨 후, Na2CO3 100ul를 첨가하였다. 30분 후 730nm의 흡광도를 측정하고 표준물질인 갈릭산 (gallic acid)과 탄닉산 (tannic acid)의 검량곡선에 대입하여 gallic acid equivalent mg/g, tannic acid equivalent mg/g 추출물로 총 폴리페놀 함량을 측정하였다. 그 결과, 표 1과 같은 결과를 얻었다.
10 mg of a sample of the cochlea extract obtained according to the example was diluted in distilled water. 20ul of the diluted sample was put into a 96-well plate, and 60ul of distilled water was added thereto to dilute to 80ul. To this was added 20 ul of Folin-Ciocaltene reagent and allowed to react for 5 minutes, followed by the addition of 100 ul of Na 2 CO 3 . After 30 minutes, the absorbance at 730 nm was measured, and it was substituted into the calibration curves of gallic acid and tannic acid, which are standard substances, and the total polyphenol content as gallic acid equivalent mg / g and tannic acid equivalent mg / Were measured. As a result, the results shown in Table 1 were obtained.
상기 표 1에 의해 본 발명의 활성 성분인 동자꽃 추출물이 항산화능을 가지는 것을 확인할 수 있었다.
It can be confirmed from the above Table 1 that the plant extract of the present invention as an active ingredient of the present invention has an antioxidant ability.
[[ 실험예Experimental Example 7] 7]
동자꽃 추출물 내 총 플라보노이드 함량 측정Total flavonoid content in flower bud extract
실시예에 의하여 얻어진 동자꽃 추출물 시료 10mg을 증류수에 희석하였다. 희석한 시료 20ul를 96-웰에 넣고 다시 80ul의 증류수를 넣어 100ul 가 되도록 희석하였다. 여기에 100ul의 AlCl36H2O를 첨가하여 5분간 반응시켰다. 그 후, 430nm의 흡광도를 측정하여 표준물질인 quercetin의 검량 선에 대입하여 총 플라보노이드 함량을 비교하였고 quercetin equivalent mg/g 추출물로 측정하였다. 그 결과, 표 2와 같은 결과를 얻었다.
10 mg of a sample of the cochlea extract obtained according to the example was diluted in distilled water. 20ul of diluted sample was added to 96-well, and then 80ul of distilled water was added to dilute to 100ul. Here the addition of AlCl 3 6H 2 O in 100ul reaction was carried out for 5 minutes. After that, the absorbance at 430 nm was measured, and the total flavonoid content was compared with the calibration curve of quercetin, which was a standard substance, and quercetin equivalent mg / g extract was measured. As a result, the results shown in Table 2 were obtained.
상기 표 2에 의하여 본 발명의 활성 성분인 동자꽃 추출물이 항산화능을 가지는 것을 확인할 수 있었다.
The results are shown in Table 2, and it can be confirmed that the plant extracts of the present invention as an active ingredient of the present invention have antioxidant ability.
아래 상기 조성물의 제형예를 설명하나, 이는 본 발명을 한정하는 것이 아니라 단지 구체적으로 설명하고자 함이다.
Formulation examples of the composition are described below, but are not intended to limit the invention, but merely to illustrate the invention.
[제제예 1] 연질 캡슐[Formulation Example 1] Soft capsule
동자꽃 식물 추출물 80mg, 비타민 E 9mg, 비타민 C 9mg, 팜유 2mg, 식물성 경화유 8mg, 황납 4mg 및 레시틴 9mg을 혼합하고, 통상의 방법에 따라 혼합하여 연질 캡슐 충진액을 제조한다. 1 캡슐당 400㎎씩 충진하여 연질 캡슐을 제조한다. 그리고, 상기와 별도로 젤라틴 66 중량부, 글리세린 24 중량부 및 솔비톨액 10 중량부의 비율로 연질 캡슐 시트를 제조하고 상기 충진액을 충진시켜 본 발명에 따른 조성물 400mg이 함유된 연질 캡슐을 제조한다.
A soft capsule filling liquid is prepared by mixing 80 mg of plant extract, 9 mg of vitamin E, 9 mg of vitamin C, 2 mg of palm oil, 8 mg of vegetable hardening oil, 4 mg of yellow pear and 9 mg of lecithin. 400 mg per capsule is filled to prepare a soft capsule. Separately from this, a soft capsule sheet was prepared in a ratio of 66 parts by weight of gelatin, 24 parts by weight of glycerin and 10 parts by weight of sorbitol, and filled with the filling solution to prepare a soft capsule containing 400 mg of the composition of the present invention.
[제제예 2] 정제 [Formulation Example 2] Tablets
동자꽃 식물 추출물 80mg, 비타민 E 9mg, 비타민 C 9mg, 갈락토올리고당 200㎎, 유당 60㎎ 및 맥아당 140㎎을 혼합하고 유동층 건조기를 이용하여 과립한 후 당 에스테르(sugar ester) 6㎎을 첨가한다. 이들 조성물 500mg을 통상의 방법으로 타정하여 정제를 제조한다.
After mixing with 80 mg of plant extract, 9 mg of vitamin E, 9 mg of vitamin C, 200 mg of galactooligosaccharide, 60 mg of lactose and 140 mg of maltose, the mixture is granulated using a fluidized bed drier and 6 mg of sugar ester is added. 500 mg of these compositions are tabletted by conventional methods to prepare tablets.
[제제예 3] 드링크제 [Formulation Example 3] Drug agent
동자꽃 식물 추출물 80mg, 비타민 E 9mg, 비타민 C 9mg, 포도당 10g, 구연산 0.6g, 및 액상 올리고당 25g을 혼합한 후, 정제수 300㎖를 가하여 각 병에 200㎖씩 되도록 충진한다. 병에 충진한 후 130℃에서 4?5초간 살균하여 드링크제를 제조한다.After mixing 80 mg of plant extract, 9 mg of vitamin E, 9 mg of vitamin C, 10 g of glucose, 0.6 g of citric acid and 25 g of liquid oligosaccharide, 300 ml of purified water is added, and 200 ml of each is injected into each bottle. It is filled in a bottle and sterilized at 130 ° C for 4 to 5 seconds to prepare a drink.
[제제예 4] 과립제[Formulation Example 4] Granules
동자꽃 식물 추출물 80mg, 비타민 E 9mg, 비타민 C 9mg, 무수결정 포도당 250㎎ 및 전분 550㎎을 혼합하고, 유동층 과립기를 사용하여 과립으로 성형한 후 포에 충진하여 과립제를 제조한다.
The plant extract powder (80 mg), vitamin E (9 mg), vitamin C (9 mg), anhydrous crystalline glucose (250 mg) and starch (550 mg) were mixed and granulated using a fluidized bed granulator to form granules.
본 발명이 속한 분야에서 통상의 지식을 가진 자라면 상기 내용을 바탕으로 본 발명의 범주 내에서 다양한 응용 및 변형을 행하는 것이 가능할 것이다.
Those skilled in the art will appreciate that various modifications, additions and substitutions are possible, without departing from the scope and spirit of the invention as disclosed in the accompanying claims.
[제제예 5] 건강 음료의 제조 [Formulation Example 5] Preparation of health drinks
동자꽃 식물 추출물................................... 1000 ㎎ Flower extract of plant ................................... 1000 mg
구연산..................................................... 1000 ㎎ Citric acid ................................................. ... 1000 mg
올리고당..................................................... 100 g oligosaccharide................................................. .... 100 g
매실농축액..................................................... 2 g Plum concentrate ................................................ ..... 2 g
타우린............................................................ 1 g Taurine ................................................. ........... 1 g
정제수를 가하여 전체......................... 900 ㎖Purified water was added to the mixture to complete 900 ml
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2ℓ용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다.The above components were mixed according to a conventional health drink manufacturing method, and the mixture was heated at 85 DEG C for about 1 hour with stirring, and the solution thus prepared was filtered to obtain a sterilized 2-liter container, which was sealed and sterilized, ≪ / RTI >
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만 수요계층이나, 수요국가, 사용 용도 등 지역적, 민족적 기호도에 따라서 그 배합비율을 임의로 변형 실시하여도 무방하다. 본 발명이 속한 기술 분야에서 통상의 지식을 가진 자라면 상기 내용을 바탕으로 본 발명의 범주 내에서 다양한 응용 및 변형을 행하는 것이 가능할 것이다.
Although the composition ratio is relatively mixed with a component suitable for a favorite drink, it is also possible to arbitrarily modify the blending ratio according to the regional or national preference such as the demand level, the demanding country, the use purpose, and the like. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.
[제형예 1] 유연화장수(스킨로션)[Formulation Example 1] Softening lotion (skin lotion)
[제형예 2] 영양화장수(밀크로션)[Formulation Example 2] Nutritional lotion (Milk lotion)
[제형예 3] 영양크림[Formulation Example 3] Nourishing cream
[제형예 4] 마사지 크림[Formulation Example 4] Massage cream
[제형예 5] 팩[Formulation Example 5] Pack
이상으로 본 발명 내용의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적 기술은 단지 바람직한 실시태양일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다고 할 것이다.While the present invention has been particularly shown and described with reference to specific embodiments thereof, those skilled in the art will readily appreciate that many modifications are possible in the exemplary embodiments without materially departing from the novel teachings and advantages of this invention. something to do. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.
Claims (10)
A cosmetic composition for antioxidation comprising an extract of Lychnis cognata as an active ingredient and having DPPH radical scavenging activity.
상기 동자꽃 추출물은 동자꽃 뿌리의 추출물인, 항산화용 화장료 조성물.
The method according to claim 1,
Wherein said flower extract is an extract of flower buds.
상기 동자꽃 추출물은 조성물 총 중량에 대하여 0.00001 내지 20.0 중량%로 포함하는, 항산화용 화장료 조성물.
The method according to claim 1,
Wherein said flower extract is contained in an amount of 0.00001 to 20.0% by weight based on the total weight of the composition.
An antioxidant health food composition comprising an extract of Lychnis cognata as an active ingredient and having DPPH radical scavenging activity.
상기 동자꽃 추출물은 동자꽃 뿌리의 추출물인, 항산화용 건강식품 조성물.
5. The method of claim 4,
Wherein said plant extract is an extract of plant extracts.
상기 동자꽃 추출물은 조성물 총 중량에 대하여 0.00001 내지 20.0 중량%로 포함하는, 항산화용 건강식품 조성물. 5. The method of claim 4,
Wherein said flower extract is contained in an amount of 0.00001 to 20.0% by weight based on the total weight of the composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140009097A KR101626108B1 (en) | 2014-01-24 | 2014-01-24 | Composition containing lobate campion extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140009097A KR101626108B1 (en) | 2014-01-24 | 2014-01-24 | Composition containing lobate campion extract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20150088593A KR20150088593A (en) | 2015-08-03 |
| KR101626108B1 true KR101626108B1 (en) | 2016-05-31 |
Family
ID=53872972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020140009097A KR101626108B1 (en) | 2014-01-24 | 2014-01-24 | Composition containing lobate campion extract |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101626108B1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003113030A (en) * | 2001-09-28 | 2003-04-18 | Ts Aasu:Kk | Skin care preparation |
-
2014
- 2014-01-24 KR KR1020140009097A patent/KR101626108B1/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003113030A (en) * | 2001-09-28 | 2003-04-18 | Ts Aasu:Kk | Skin care preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150088593A (en) | 2015-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101839407B1 (en) | Composition comprising actinidia polygama extract for improving skin whitening or wrinkle | |
| KR20210087405A (en) | Compositions Containing Plant Extracts | |
| KR102236071B1 (en) | Composition for Improving Skin Trouble Using an Extract of Centella asiatica or Paeonia lactiflora Cultured with Magma Seawater | |
| KR20180007834A (en) | Composition for cell regeneration comprising extract of ginseng floral axis | |
| KR102371417B1 (en) | Composition for anti inflammation comprising extract of ginseng floral axis | |
| KR101861094B1 (en) | Composition for improving wrinkles containing plant extract | |
| KR101447007B1 (en) | Composition for antiaging comprising the extract of Dipterocarpus obtusifolius Teijsm. Ex Miq. as an active ingredient | |
| KR20110130132A (en) | Antioxidant composition containing p. nepalensis and p. japonica extracts | |
| KR101863117B1 (en) | Composition comprising Androsace umbellate extract, Vaccinium oldhami extract, and Deutzia crenata extract | |
| KR101063351B1 (en) | The extracts and fractions of Hippophae rhamnoides L. | |
| KR102154139B1 (en) | Composition comprising fermentation of sap of painted maple, cacao nibs extract and granat extract | |
| KR101913125B1 (en) | Composition containing prunus maximowiczii extract | |
| KR101626108B1 (en) | Composition containing lobate campion extract | |
| KR101844890B1 (en) | Composition for preventing or improving atopic dermatitis comprising ethyl acetate fraction of methanol extract from Diospyros lotus leaf as effective component | |
| KR101551106B1 (en) | A composition comprising the extract of Paspalum thunbergii Kunth | |
| KR101814695B1 (en) | Composition containing prunus maximowiczii extract | |
| KR20170000366A (en) | Composition for antioxidant, and anti-inflammation effect comprising Cirtus extract and Hylotelephium erythrostictum extract | |
| KR101661423B1 (en) | anti-oxidant and anti-inflammation composition extracted from Isodon excisus, and its extracting method | |
| KR101658429B1 (en) | Composition for preventing or improving atopic dermatitis comprising supercritical fluid extract of persimmon peel as effective component | |
| KR102326592B1 (en) | Method to extract natural product using dry ice and composition containing extract obtained therefrom | |
| KR20190070569A (en) | Composition for anti-oxidant, skin whitening and anti-wrinkle effect comprising Glehnia Radix leaf extract as effective component | |
| KR101988988B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant and skin whitening | |
| US10682384B2 (en) | Composition comprising natural complex extract as active ingredient | |
| KR101425560B1 (en) | Composition for antioxidant comprising extracts or its fractions of Elaeocarpus petiolatus as an active ingredient | |
| KR101809200B1 (en) | Method for increasing effect of improving wrinkle of sasa borealis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20190520 Year of fee payment: 4 |